Our Promise to you:
Premier global microbiological solutions, extensive collection of products.
24x7 CUSTOMER SERVICE
CONTACT US TO ORDER
Programmed death ligand-1 (also known as PD-L1or CD274) on the cell surface binds to PD1 on an immune cell surface, which inhibits T cell activity by forming a biochemical "shield" protecting tumor cells from being destroyed by the immune system. Antibodies that bind to PD-L1 and therefore block the interaction may allow the T-cells to attack the tumor. Immune checkpoint blockade therapies targeting PD-L1 have been shown promising therapeutic efficacy in a variety of tumors.
Many cancer immunotherapy agents that target the PD-L1 receptor have been developed. To date, three antibody-based inhibitors targeting PD-L1 (avelumab, atezolizumab, and durvalumab) have been approved by the Food and Drug Administration (FDA). Oncolytic bacteria tumor therapy is an emerging field in the fight against cancer.
Creative Biogene is a leading company offering the best microbial genome editing service. Our talented scientists have extensive experience in gene knockout, knock-in/replacement and site-directed mutagenesis. They would research closely with you to produce nanobodies—segments of antibodies—that block a molecule on cancer cells called PD-L1 on immune cells.
Creative Biogene is the premier institution to provide professional and comprehensive genome editing services in microbial. Creative Biogene is dedicated to providing Complete Solutions for oncolytic bacteria genome editing to help you every step of the way in your genome editing workflow. We have years of experience to meet your specific project needs in using the homologous recombination or CRISPR technology to add value to your research project. We can do the co-research with you, and we think the result will be better with our experts working together.
1. Akinleye, A., Rasool, Z. Immune checkpoint inhibitors of PD-L1 as cancer therapeutics. J Hematol Oncol 12, 92 (2019).